Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network)

Systemic amyloidosis arises from monoclonal CD38+ plasma cells that produce misfolded immunoglobulin light chains, which form amyloid fibrils that are deposited into different tissues, leading to organ damage. Daratumumab is a human IgG/k monoclonal antibody that targets CD38, a glycoprotein uniform...

Full description

Saved in:
Bibliographic Details
Published inJournal of personalized medicine Vol. 12; no. 3; p. 484
Main Authors Sammartano, Vincenzo, Antonioli, Elisabetta, Buda, Gabriele, Ciofini, Sara, Candi, Veronica, Pengue, Ludovica, Del Giudice, Maria Livia, Attucci, Irene, Bacchiarri, Francesca, Occhini, Ubaldo, Pirrotta, Maria Teresa, Perfetto, Federico, Bocchia, Monica, Gozzetti, Alessandro
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 17.03.2022
MDPI
Subjects
Amyloid
Amyloidosis
Biopsy
CD38 antigen
Cloning
Fibrils
Hematology
Immunoglobulin G
Immunoglobulins
Light chains
Medical prognosis
Monoclonal antibodies
Multiple myeloma
Patients
Plasma cells
Precision medicine
Stem cells
Survival analysis
Toxicity
Transplants & implants
Ultrasonic imaging
Urine
multiple myeloma
amyloidosis
daratumumab
real-life
Online AccessGet full text

Cover

More Information
Summary:Systemic amyloidosis arises from monoclonal CD38+ plasma cells that produce misfolded immunoglobulin light chains, which form amyloid fibrils that are deposited into different tissues, leading to organ damage. Daratumumab is a human IgG/k monoclonal antibody that targets CD38, a glycoprotein uniformly expressed on human plasma cells. Daratumumab has been utilized in recent years with unprecedented responses in multiple myeloma. In patients with relapsed or refractory AL amyloidosis, daratumumab has shown promising efficacy in terms of hematologic responses and improvement in organ function. Here, we report real-life treatment with Daratumumab in 33 AL amyloidosis patients treated within the Regional Tuscan Myeloma network at 5 centers with associated MGUS or SMM ( = 15) or symptomatic MM ( = 18). Patients were treated at relapsed/refractory disease stages ( = 29) with a median of one previous line of therapy or at diagnosis ( = 4). Daratumumab showed good efficacy, representing 60% of good hematological responses and 50% of organ responses in a real-life population of patients with an acceptable toxicity profile.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2075-4426
2075-4426
DOI:10.3390/jpm12030484